Schering-Plough Hopes Duke Biomarker Finding will Yield Companion Dx for HCV Rxs

Schering-Plough owns the IP rights to the drug-response marker and is contemplating further developing and marketing a diagnostic based on it that could accompany its current marketed interferon-based HCV treatment.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.